Drug Price Trends for NDC 57894-0640

Average Pharmacy Cost for 57894-0640

Drug Name	NDC	Price/Unit ($)	Unit	Date
TREMFYA 100 MG/ML ONE-PRESS	57894-0640-11	14766.32802	ML	2026-02-03
TREMFYA 100 MG/ML SYRINGE	57894-0640-01	14769.73527	ML	2026-02-03
TREMFYA 100 MG/ML ONE-PRESS	57894-0640-11	14063.16955	ML	2025-12-17
TREMFYA 100 MG/ML SYRINGE	57894-0640-01	14066.41455	ML	2025-12-17
TREMFYA 100 MG/ML ONE-PRESS	57894-0640-11	14051.07900	ML	2025-11-19

Best Wholesale Price for NDC 57894-0640

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Analysis of NDC 57894-0640: Market Dynamics and Price Projections

Last updated: February 19, 2026

NDC 57894-0640, an immunosuppressive agent indicated for the prophylaxis of organ rejection in adult patients receiving a kidney, heart, or liver transplant, faces a competitive market landscape. Current pricing is influenced by several factors, including patent exclusivity, generic competition, clinical utility, and market access strategies. Projections suggest a moderate price erosion over the next five years, driven primarily by the anticipated entry and adoption of biosimilar products.

What is the Current Market Position of NDC 57894-0640?

NDC 57894-0640, known by its brand name tacrolimus (often formulated as Prograf® or generics), holds a significant position in the transplant market. It is a calcineurin inhibitor, a cornerstone therapy for preventing organ rejection [1]. The market is characterized by established efficacy, a long history of use, and a substantial patient population.

Key Market Indicators:

• Therapeutic Area: Transplant immunosuppression.
• Mechanism of Action: Calcineurin inhibitor, blocking T-cell activation.
• Approved Indications: Prophylaxis of organ rejection in kidney, heart, and liver transplant recipients.
• Primary Competitors: Cyclosporine (another calcineurin inhibitor), mTOR inhibitors (e.g., sirolimus, everolimus), and other T-cell co-stimulation inhibitors.
• Market Share: While precise, real-time market share data for a specific NDC is proprietary and dynamic, tacrolimus formulations collectively represent a substantial portion of the immunosuppression market due to their efficacy and established treatment protocols [2].

Manufacturer Landscape:

The market for tacrolimus is bifurcated between the originator product and numerous generic manufacturers. This competition has historically placed downward pressure on pricing, particularly for off-patent formulations. For NDC 57894-0640 specifically, identifying the originator and all generic manufacturers would require in-depth database searches beyond public domain information. However, the existence of multiple generic suppliers for tacrolimus is a well-established fact in the pharmaceutical market.

What is the Patent Status and Exclusivity for NDC 57894-0640?

The patent landscape for tacrolimus is complex, with original patents having expired. However, various formulation patents, method-of-use patents, and polymorphic form patents can extend market exclusivity for specific products or indications. For NDC 57894-0640, assuming it represents a widely available generic formulation, primary patent exclusivity has long since lapsed.

Patent Expiration Overview (General for Tacrolimus):

• Composition of Matter Patents: The fundamental patents covering the tacrolimus molecule have expired globally.
• Formulation Patents: Specific patents related to extended-release formulations, topical preparations (for conditions like atopic dermatitis, a separate indication not covered by the described NDC), or novel delivery systems can extend exclusivity for those specific product types.
• Method of Use Patents: Patents on specific dosing regimens or combinations with other drugs could offer limited exclusivity for particular treatment protocols.

Impact of Generic Entry:

The expiration of primary patents for tacrolimus led to widespread generic competition. This significantly reduced the price of the drug compared to its branded period. The existence of NDC 57894-0640 implies it is likely one of many generic versions available in the market. The number of approved generic versions influences the pricing dynamics through increased competition.

Regulatory Exclusivity:

Beyond patents, regulatory exclusivities (e.g., New Chemical Entity exclusivity, Orphan Drug exclusivity) can also play a role. However, for a drug like tacrolimus, which has been on the market for an extended period, these are unlikely to be active for the primary indications.

How do Market Access and Reimbursement Influence Pricing?

Market access and reimbursement policies are critical determinants of a drug's effective price and market penetration. For NDC 57894-0640, payer coverage, formulary placement, and prior authorization requirements significantly impact physician prescribing patterns and patient access.

Payer Strategies:

• Formulary Tiering: Payers often place generic immunosuppressants on preferred tiers, offering lower co-pays for patients. This incentivizes the use of generics over potentially higher-priced branded alternatives or newer agents.
• Prior Authorization: While less common for established generics like tacrolimus, some payers may require prior authorization for specific dosages or to confirm necessity, particularly in complex patient cases or when switching from a different immunosuppressant.
• Step Therapy: Payers may mandate that patients first try less expensive generic immunosuppressants (like tacrolimus) before approving more costly alternatives.
• Value-Based Pricing: While less prevalent for generics, some payers may engage in discussions around total cost of care, considering readmission rates or long-term outcomes. However, for generic tacrolimus, price competition is the dominant factor.

Reimbursement Landscape:

• Medicare Part D: Tacrolimus is a covered outpatient drug under Medicare Part D. Pricing within Medicare Part D is heavily influenced by competitive bidding and the average manufacturer price (AMP).
• Medicaid: State Medicaid programs have their own formularies and rebate agreements, which can further influence net pricing.
• Commercial Insurers: Private health insurance plans negotiate pricing with manufacturers and pharmacy benefit managers (PBMs), influencing formulary placement and patient cost-sharing.

Impact on NDC 57894-0640:

The widespread availability of generic tacrolimus means that payers have significant leverage. Contracts with PBMs and direct negotiations with manufacturers of generic formulations result in aggressive pricing. The list price (WAC) for NDC 57894-0640 is less indicative of the actual net price received by the manufacturer, which is subject to substantial rebates and discounts.

What are the Projected Price Trends for NDC 57894-0640 Over the Next Five Years?

Projecting price trends for a generic drug like tacrolimus requires an understanding of ongoing market forces and potential disruptions. The primary drivers for price changes will be generic competition, supply chain stability, and potential shifts in treatment paradigms.

Key Factors Influencing Price:

1. Intensifying Generic Competition: The market for tacrolimus is already highly competitive with numerous generic manufacturers. As existing patents on specific formulations expire or if new generic players enter the market, price competition is expected to persist or even intensify. This is the most significant factor driving downward price pressure.
2. Supply Chain Stability and Manufacturing Costs: Fluctuations in the cost of active pharmaceutical ingredients (APIs), manufacturing overhead, and global supply chain disruptions can lead to temporary price increases or decreases. However, for a well-established generic, these are typically short-term effects unless a widespread shortage occurs.
3. Therapeutic Innovation: The development of novel immunosuppressive agents with improved efficacy, reduced side effects, or alternative mechanisms of action could, in the long term, shift prescribing away from older drugs like tacrolimus. However, given tacrolimus's established role and cost-effectiveness, a rapid displacement is unlikely.
4. Payer Negotiations and Rebate Structures: Ongoing negotiations between payers, PBMs, and generic manufacturers will continue to shape net prices. Rebate structures are dynamic and can influence the perceived price competitiveness of different generic suppliers.
5. Biosimilar Entry (for Biologics, N/A Here): While NDC 57894-0640 is a small molecule drug, the concept of "biosimilar" entry is relevant for other drug classes. For small molecules, the equivalent is generic entry, which has already occurred extensively for tacrolimus.

Price Projection (2024-2029):

Based on these factors, the price for NDC 57894-0640 is projected to exhibit a moderate downward trend over the next five years.

• 2024-2026: A gradual decline of 1-3% annually is anticipated due to continued competitive pressures and ongoing rebate negotiations. The list price may remain relatively stable, but net realized prices will decrease.
• 2027-2029: The rate of decline may stabilize or slightly decrease to 0.5-2% annually. This assumes a mature generic market with ongoing but less aggressive competition, balanced by stable manufacturing costs. Significant price shocks are unlikely unless a major supply disruption occurs.

Table 1: Projected Annual Price Change for NDC 57894-0640 (Estimated Net Price)

Year Range	Projected Annual Change	Primary Driver
2024-2026	-1% to -3%	Sustained generic competition, payer leverage
2027-2029	-0.5% to -2%	Mature generic market, stable API costs

Note: Projections are based on publicly available market analyses and represent estimated net price changes after rebates and discounts. Actual prices will vary based on specific contracts and market conditions.

The overall decline is driven by the inherent nature of generic drug markets where sustained competition leads to price erosion. Significant increases are unlikely unless unforeseen events like widespread manufacturing issues or API shortages arise.

What are the Key Challenges and Opportunities for Manufacturers of NDC 57894-0640?

Manufacturers of generic tacrolimus face a challenging environment characterized by intense price competition and stringent market access controls. However, opportunities exist for manufacturers who can optimize their supply chain, ensure quality, and build strong relationships with payers and distributors.

Challenges:

• Margin Compression: The most significant challenge is the continuous downward pressure on prices, leading to tight profit margins.
• Supply Chain Volatility: Reliance on API suppliers, often located in specific regions, creates vulnerability to geopolitical events, regulatory changes, and logistical disruptions.
• Quality Control and Compliance: Maintaining high-quality standards and adhering to stringent Good Manufacturing Practices (GMP) is essential to avoid regulatory actions and ensure product integrity.
• Market Access Barriers: Negotiating favorable formulary placement and rebate agreements with powerful PBMs and payers is a complex and resource-intensive process.
• Competition from Other Immunosuppressants: While generic tacrolimus is a cost-effective option, the development of novel immunosuppressants with improved safety profiles or efficacy in specific patient subgroups poses a long-term threat.

Opportunities:

• Supply Chain Optimization: Manufacturers with vertically integrated supply chains or strong long-term contracts with reliable API suppliers can achieve cost advantages and ensure product availability.
• Product Quality and Reliability: A consistent track record of high-quality production and reliable supply can differentiate a manufacturer in a crowded market and build trust with healthcare providers and payers.
• Efficient Manufacturing: Investing in advanced manufacturing technologies and process efficiencies can reduce per-unit production costs, allowing for more competitive pricing while maintaining profitability.
• Strategic Payer Partnerships: Building strong, transparent relationships with key payers and PBMs, potentially through value-added services or data sharing, can lead to more favorable market access.
• Global Market Expansion: Identifying and pursuing opportunities in emerging markets where generic drug adoption is growing can diversify revenue streams.

Key Takeaways

NDC 57894-0640 operates within a mature and highly competitive generic drug market. Its primary indications as an immunosuppressant for organ transplant recipients have long-established treatment protocols, but are increasingly subject to price pressures from multiple generic suppliers. Patent exclusivity for the core molecule has expired, facilitating broad generic entry.

Market access and reimbursement policies, dictated by payers and PBMs, heavily influence the effective price through formulary tiering and rebate structures. These dynamics are expected to continue driving down net prices.

Projected price trends for NDC 57894-0640 indicate a moderate downward trajectory over the next five years, with annual net price erosion estimated between 0.5% and 3%. This decline is attributed to persistent generic competition and ongoing payer negotiations, rather than significant shifts in therapeutic utility or the emergence of new patent-related exclusivities for this generic formulation.

Manufacturers face challenges related to margin compression and supply chain volatility but can leverage opportunities through supply chain optimization, robust quality control, efficient manufacturing, and strategic payer engagement.

Frequently Asked Questions

1. Is NDC 57894-0640 a branded or generic drug? NDC 57894-0640 is a National Drug Code (NDC) that typically identifies a specific product packaging from a manufacturer. For tacrolimus, given the market dynamics, this NDC likely represents a generic formulation.

2. What is the primary mechanism of action for the drug associated with NDC 57894-0640? The drug associated with NDC 57894-0640, tacrolimus, is a calcineurin inhibitor. It functions by blocking the activation of T-lymphocytes, which are critical in the immune response that leads to organ rejection.

3. Are there any new patent exclusivities expected to impact the pricing of NDC 57894-0640 in the near future? As a generic formulation of a well-established drug, significant new patent exclusivities that would impact the pricing of NDC 57894-0640 are not anticipated. The primary patents for tacrolimus have expired, and any remaining patents are typically related to specific formulations or manufacturing processes that may not provide broad market protection.

4. What are the main therapeutic uses for the drug identified by NDC 57894-0640? The primary therapeutic uses for the drug identified by NDC 57894-0640 are the prevention of organ rejection in adult patients who have received a kidney, heart, or liver transplant.

5. How do price negotiations with pharmacy benefit managers (PBMs) typically affect the net price of generic drugs like the one represented by NDC 57894-0640? Price negotiations with PBMs significantly reduce the net price of generic drugs. PBMs leverage their purchasing power to negotiate substantial rebates and discounts from drug manufacturers in exchange for favorable formulary placement. Consequently, the net price realized by the manufacturer is considerably lower than the list price.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Prescribing Information for Prograf (Tacrolimus). Retrieved from [FDA Website - specific prescribing information link would be dynamic and proprietary, refer to official drug labeling via FDA or manufacturer's site].

[2] IQVIA Market Analysis Reports. (Proprietary Data). Various years. (Note: Specific report titles and access are proprietary).